SCHEMBL13101028

SCHEMBL13101028

CC(C)C(=O)C(=O)NCc1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.61
KMT2A Q03164 1/20 0.61
RECQL P46063 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.58
HTT P42858 3/20 0.57
LMNA P02545 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
MAPT P10636 1/20 0.56
CTSK P43235 1/20 0.56
HPGD P15428 2/20 0.55
ALDH1A1 P00352 2/20 0.55
POLB P06746 1/20 0.55
FES P07332 1/20 0.55
RET P07949 1/20 0.55
MARK3 P27448 1/20 0.55
TYK2 P29597 1/20 0.55
FLT4 P35916 1/20 0.55
SYK P43405 1/20 0.55
CLK2 P49760 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10311689 0.84 PKM (0.73) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL19500126 0.84 HPGD (0.58) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL13113099 0.83 RECQL (0.66) PKMKMT2ARECQLHTTLMNA
SCHEMBL12330547 0.81 KMT2A (0.56) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL23835832 0.81 HTT (0.59) L3MBTL1HTTLMNAMAPTCTSK
SCHEMBL7761446 0.81 HPGD (0.61) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL21845945 0.81 L3MBTL1 (0.64) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL17754234 0.80 ALDH1A1 (0.67) KMT2AL3MBTL1MAPTHPGDALDH1A1
SCHEMBL2699237 0.80 RECQL (0.62) PKMKMT2ARECQLL3MBTL1HTT
SCHEMBL13130716 0.80 RECQL (0.62) PKMKMT2ARECQLHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-06-22 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-04-26 US disclosed
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2021-11-18 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-09-21 US disclosed
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof CTSV, CTRL, CTSL PKM 2706/4885KMT2A 3478/4885RECQL 1560/4885
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL PKM 3076/4885KMT2A 3130/4885RECQL 1715/4885
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PKM 2843/4885KMT2A 3255/4885RECQL 558/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PKM 3076/4885KMT2A 3130/4885RECQL 1715/4885
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL PKM 2706/4885KMT2A 3478/4885RECQL 1560/4885
US-20100256355-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING NR0B2, NR0B1, NR2C2 PKM 4747/4885KMT2A 3553/4885RECQL 1759/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL PKM 3076/4885KMT2A 3130/4885RECQL 1715/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV PKM 2707/4885KMT2A 3383/4885RECQL 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.